ENHO and metabolic dysfunction-associated steatotic liver disease: Clinical studies suggested that serum adropin was reduced in many diseases, such as NAFLD, T2DM, diabetic nephropathies, coronary atherosclerosis, hypertension, and polycystic ovary disease (Jasaszwili et al., 2020; Ye et al., 2021).